Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 6/20 | 0.57 |
| ▸ | KCNQ3 | O43525 | 4/20 | 0.57 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.56 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.56 |
| ▸ | MAOB | P27338 | 8/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5087179 | 0.89 | MAOB (0.54) | KCNQ2KCNQ3MAOBFFAR1 | |
| SCHEMBL5090811 | 0.88 | KCNQ2 (0.65) | KCNQ2KCNQ3KCNQ4KCNQ5MAOB | |
| SCHEMBL5089465 | 0.88 | CYP1A2 (0.55) | KCNQ2KCNQ3KCNQ4KCNQ5MAOB | |
| SCHEMBL5087377 | 0.85 | MAOA (0.52) | KCNQ2KCNQ3KCNQ4KCNQ5MAOB | |
| SCHEMBL5090320 | 0.85 | ALDH1A1 (0.53) | KCNQ2KCNQ3KCNQ4KCNQ5MAOB | |
| SCHEMBL5090792 | 0.84 | KCNQ2 (0.55) | KCNQ2KCNQ3KCNQ4KCNQ5MAOB | |
| SCHEMBL5089204 | 0.83 | LNPEP (0.55) | KCNQ2KCNQ3KCNQ4KCNQ5MAOB | |
| SCHEMBL5090177 | 0.83 | KCNQ2 (0.49) | KCNQ2KCNQ3KCNQ4KCNQ5PPARG | |
| SCHEMBL5090219 | 0.83 | KCNQ2 (0.44) | KCNQ2KCNQ3KCNQ4KCNQ5MAOB | |
| SCHEMBL5090791 | 0.83 | KCNQ2 (0.59) | KCNQ2KCNQ3KCNQ4KCNQ5MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188561-A1 | N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS | JPMORGAN CHASE BANK, N.A. | 2008-08-07 | — | — | US | claimed |
| US-8722929-B2 | N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2014-05-13 | — | — | US | disclosed |
| US-20080188561-A1 | N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS | JPMORGAN CHASE BANK, N.A. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188561-A1 | N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS | KCNB2, KCNJ2, KCNA2 | KCNQ2 9/4885KCNQ3 32/4885KCNQ4 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.